Huafu Securities released a research report on April 18 stating that it gave Shenzhou Cell (688520.SH) a purchase rating, and the target price was 62.84 yuan. The main reasons for the rating include: 1) the product matrix is beginning to take shape, and it has entered the national health insurance catalogue in 24 years and is expected to be rapidly scaled up; 2) the growth rate of R&D expenses is slowing down, and multiple competitive research pipelines are promoting clinical trials. (Mainichi Keizai Shimbun)
华福证券4月18日发布研报称，给予神州细胞（688520.SH）买入评级，目标价格为62.84元。评级理由主要包括：1）产品矩阵初具规模，24年已进入国家医保目录有望快速放量；2）研发费用增速放缓，多个具备竞争力的在研管线推进临床。（每日经济新闻）
Huafu Securities released a research report on April 18 stating that it gave Shenzhou Cell (688520.SH) a purchase rating, and the target price was 62.84 yuan. The main reasons for the rating include: 1) the product matrix is beginning to take shape, and i
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.